{"id":"NCT00955825","sponsor":"Stallergenes Greer","briefTitle":"Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Adult Patients Suffering From Grass Pollen Rhinoconjunctivitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2009-08-10","resultsPosted":"2016-05-19","lastUpdate":"2016-05-19"},"enrollment":473,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Allergic Rhinitis Due to Grass Pollens"],"interventions":[{"type":"DRUG","name":"300 IR","otherNames":["Sublingual immunotherapy tablet"]},{"type":"DRUG","name":"Placebo","otherNames":["Sublingual placebo tablet"]}],"arms":[{"label":"300 IR","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to assess the efficacy and safety of 300 IR sublingual tablet of grass pollen allergen extract compared to placebo in adult patient with allergic rhinoconjunctivitis.","primaryOutcome":{"measure":"Combined Score (CS)","timeFrame":"Pollen period (average of 42.8 days)","effectByArm":[{"arm":"300 IR","deltaMin":0.32,"sd":0.033},{"arm":"Placebo","deltaMin":0.45,"sd":0.032}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":19,"countries":["United States"]},"refs":{"pmids":["23122534"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":233},"commonTop":["NASOPHARYNGITIS","ORAL PRURITUS","THROAT IRRITATION","HEADACHE","UPPER RESPIRATORY TRACT INFECTION"]}}